David B Goldstein

机构：New South Wales Department of Health, Cancer Institute of New South Wales, UNSW Sydney, Cancer Australia, Prince of Wales Hospital · ORCID：0000-0001-6142-3291

发表论文 637 篇 · 总被引 31436 次 · h-index 81

代表论文

• Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group (2023 · Journal of Clinical Oncology · 被引 278)
• HGF/c-Met pathway inhibition combined with chemotherapy increases cytotoxic T-cell infiltration and inhibits pancreatic tumour growth and metastasis (2023 · Cancer Letters · 被引 21)
• Characterising vincristine-induced peripheral neuropathy in adults: symptom development and long-term persistent outcomes (2024 · Supportive Care in Cancer · 被引 13)
• Impact of Pain on Symptom Burden in Chemotherapy-Induced Peripheral Neurotoxicity (2024 · Journal of the National Comprehensive Cancer Network · 被引 11)
• Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study (2023 · European Journal of Cancer · 被引 11)
• Defining the optimal radiation thresholds for Stratifying jaw osteoradionecrosis risk in head and neck cancer (2025 · Radiotherapy and Oncology · 被引 7)